Figure 5
Figure 5. Immunoreactivity of paraproteins. Immunoreactivity of paraproteins from patients 10 to 20 with a synthetic peptide corresponding to the AD-2S1 epitope of glycoprotein B human herpesvirus 5 () or with a synthetic peptide corresponding to the amino terminus (amino acids 1-20) of the UL-48 gene product (). MM patient sera were diluted 1:1250 so as to fall within the assay linear range. An HCMV-immunoreactive serum was used as a positive (+) control. A nonreactive serum was used as a negative control (-). Since patients 12 and 20 are our index patients, we randomly included MM patients 10 to 20 in the immunoassay, for comparison. The patient selection is random, since the patient number designation is assigned in order of specimen acquisition. Samples were measured in duplicate. The mean plus or minus the standard deviation are shown.

Immunoreactivity of paraproteins. Immunoreactivity of paraproteins from patients 10 to 20 with a synthetic peptide corresponding to the AD-2S1 epitope of glycoprotein B human herpesvirus 5 () or with a synthetic peptide corresponding to the amino terminus (amino acids 1-20) of the UL-48 gene product (). MM patient sera were diluted 1:1250 so as to fall within the assay linear range. An HCMV-immunoreactive serum was used as a positive (+) control. A nonreactive serum was used as a negative control (-). Since patients 12 and 20 are our index patients, we randomly included MM patients 10 to 20 in the immunoassay, for comparison. The patient selection is random, since the patient number designation is assigned in order of specimen acquisition. Samples were measured in duplicate. The mean plus or minus the standard deviation are shown.

Close Modal

or Create an Account

Close Modal
Close Modal